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Abstract:
Objective: To estimate the treatment effect from participating in an asthma intervention that was part of
the National Asthma Control Program.
Study Setting: Data on children who participated in asthma case management (N=270) and eligible
children who did not participate in case management (N=2,742) were extracted from a claims database.
Study Design: We created 81 measures of health care utilization and 40 measures of neighborhood
characteristics that could be related to participation in the program. The participation model was selected
using the cross-validation-based Deletion Substitution and Addition (DSA) algorithm. We used optimal
full matching for the vector of Mahalanobis’ distances and propensity scores to estimate the difference
between participants and non-participants in the probability of a range of asthma outcomes.
Principal Findings: Compared to non-participants, participants were more likely to have vaccinations for
pulmonary illness, use controller medications, and have a refill for rescue medication. There was no
statistically significant difference in the number of nebulizer treatments or ED visits between the two
groups. We find that the asthma program had no significant effect on overall asthma control.
Conclusion: We are not able to discern whether the lack of an effect in overall control is due to the
effectiveness of the program, heterogeneity of effects or barriers outside the program’s control. We
discuss how current programs could be modified to better inform future research and program design.
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Estimation of Treatment Effect of Asthma Case Management
Using Propensity Score Methods

Objective: To estimate the treatment effect from participating in an asthma intervention that was
part of the National Asthma Control Program.
Study Setting: Data on children who participated in asthma case management (N=270) and
eligible children who did not participate in case management (N=2,742) were extracted from a
claims database.
Study Design: We created 81 measures of health care utilization and 40 measures of
neighborhood characteristics that could be related to participation in the program. The
participation model was selected using the cross-validation-based Deletion Substitution and
Addition (DSA) algorithm. We used optimal full matching for the vector of Mahalanobis’
distances and propensity scores to estimate the difference between participants and nonparticipants in the probability of a range of asthma outcomes.
Principal Findings: Compared to non-participants, participants were more likely to have
vaccinations for pulmonary illness, use controller medications, and have a refill for rescue
medication. There was no statistically significant difference in the number of nebulizer
treatments or ED visits between the two groups. We find that the asthma program had no
significant effect on overall asthma control
Conclusion: We are not able to discern whether the lack of an effect in overall control is due to
the effectiveness of the program, heterogeneity of effects or barriers outside the program’s
control. We discuss how current programs could be modified to better inform future research and
program design.
Key words: asthma, treatment effect, health intervention, propensity scores

1. Introduction
The most prominent example of public investment in asthma programs is the CDC’s
National Asthma Control Program. Created in 1999, the program has spent almost $208 million
(CDC, 2007) 1 on two intervention models - the Inner-City Asthma Intervention and the
Controlling Asthma in American Cities Project (CAACP). 2 Each model attempts to achieve
clinical-like results in a community setting similar to that of the National Cooperative Inner-City
Asthma Study (NCICAS). NCICAS was a family-focused program targeted at inner-city children
with moderate to severe asthma that included over one-thousand families randomized into
intervention and control groups. A master's-level asthma educator met with caregivers and
children in a combination of group classes and individualized meetings. The NCICAS
intervention was publicized as "a scientifically proven asthma intervention program" (NIH,
2001), despite the fact that the assessment of the program found no statistically significant
differences in utilization of health care between the intervention and control groups. While there
was a statistically significant difference between the intervention and control groups in the
maximum number of symptom days 3 in year one of the study, after two years, differences were
no longer significant.
During the design and implementation of the National Asthma Control Program, there
was little attention paid to assessing the effectiveness of the interventions that were funded.
While some programs have summarized process outcomes and qualitative assessments (for a
1

In 2003, the CDC spending on asthma programs ($36.9 million) was greater than for autism ($10.8 million) but
less than from diabetes ($63 million) or lead prevention programs ($42.0 million). The projects funded in 2003
included 7 tracking programs, 49 interventions and 39 community partnerships. For more information see
http://www.cdc.gov/asthma/aag07.htm#more.
2
The Inner-City Asthma Intervention was located in 23 sites. The programs all had asthma educators who were
based in health organizations that treated low-income inner-city children. Controlling Asthma in American Cities
Project (CAACP) was also based in low-income urban areas, but each intervention was locally developed and varied
in the design and components. CAACP was implemented in seven cities.
3
The number of days with asthma symptoms over a two-week period averaged over six observations during the
year.

review see the 2006 supplement to Annals of Allergy, Asthma and Immunology), there are few
data on actual health outcomes and, therefore, no rigorous evaluation of these investments to
determine if they are, in fact, the best use of available funds to reduce morbidity in childhood
asthma. At present, whether these interventions in urban communities can shift behavior from
treatment of asthma attacks to prevention of attacks through risk-reducing investments, and
whether costs can be reduced and quality of life can be improved, remains an open question.
In this paper, we examine Oakland Kicks Asthma (OKA), a case management program
that is part of the CAACP. Oakland, CA is among the most diverse cities in the United States,
with 29% of children living in poverty (U.S. Census, 2006). The annual rate of asthma-related
hospitalizations for children ages 0-14 is approximately twice that for the state (36.63 versus
18.73 per 10,000 residents/year). 4 The Oakland Kicks Asthma (OKA) case management program
was jointly developed by the American Lung Association of the East Bay and researchers at the
UC Berkeley School of Public Health. 5 Children were referred by physicians, the local Medicaid
provider or identified by surveillance surveys administered in the middle and high schools of the
Oakland Unified School District. Over three to five months, an asthma case manager visited each
participating household 3-4 times to develop an asthma management plan and assist with its
implementation. The program was free to all families.

4

The 95% confidence intervals are (34.59 to 38.72) versus (18.22 to 19.04) per 10,000 residents (Stockman et al.,
2003).
5
The asthma program, data collection tools and all protocols for protection of personal data were approved by the
Committee for the Protection of Human Subjects, UC, Berkeley.

2. Methods
Matching Participants and Non-participants
To determine the real effectiveness of the program, it is necessary to compare those
outcomes to the outcomes realized by a comparison group that did not participate in the program.
This is a non-trivial problem, because households do not randomly sort themselves into
otherwise-identical treatment and control groups. Failure to correct, as completely as possible,
for this non-random sorting will produce biased estimates of the treatment effect and a biased
assessment of the program. We address this issue by matching participants to non-participants
using the estimated propensity score. 6
For each child who is eligible to participate in OKA, there are two possible decisions,
participation and non- participation, denoted Ti=1 and Ti=0. Individuals differ on preintervention characteristics that are associated with participation (xi). The pre-intervention
variables fall into three different domains: health care use (e.g., count of pre-treatment ED
visits), socio-demographics (e.g., race), and provider and plan data (e.g., AAH health care plan
type). These domains are denoted ui , si , pi . The propensity score can be written as:
e ( xi ) ≡ pr (Ti | X i =
ui , si , pi )
One caveat of propensity scores is that results may be sensitive to misspecification of the
selection equation, especially in cases where there are quadratic terms (Drake, 1993). The
economics and public health literature provides little guidance to construct our participation
equation; thus, we rely on the cross-validation-based Deletion Substitution and Addition (DSA)
algorithm to select a participation model. The DSA is a data-adaptive selection procedure based
on cross-validation that relies on deletion, substitution, and addition moves to search through a
6

A cornerstone in evaluation methodology across disciplines is the seminal work by Rosenbaum and Rubin (1983,
1985).

large space of possible polynomial models (Moore et al., 2008). The criterion for model
selection is minimization of a loss function (empirical and cross-validated residual sum of
squares) rather than tests of significance of parameters. The result is a vector of pre-treatment
variables that includes interactions and polynomials x ∈ X . The DSA procedure is publicly
available as an R package at http://www.stat.berkeley.edu/~laan/Software/. After using the DSA
algorithm to select the model that best predicts the empirical distribution of participation,
conditional on pre-treatment variables, propensity scores are calculated by logistic regression of
participation on the selected vector xi .
We use the most flexible method to match participants to non-participants on propensity
scores, optimal full matching for the vector of Mahalanobis’ distances and propensity scores
(Haviland et al., 2007 and Hansen and Klopfer, 2006). 7 and 8 Full matching improves our
statistical power over pair matching or any other subset matching (Rosenbaum, 1989), which is
critical in our case where we have a limited number of observations on participants but a
substantially larger number of non-participants. This matching proceeds in two steps. First, the
Mahalanobis distances are defined as the difference between the vectors of pre-treatment
variables that includes the logit of the propensity score for each participant ( xi ) and nonparticipant ( x j ) pair, weighted by the inverse of the covariance matrix of the pre-treatment
variables and the logit of the propensity score, C:

7

There are several options for using the score to create comparison groups; see D'Agostino (1998) for a summary of
three approaches. While pair matching has a long history in the literature, full matching was introduced relatively
later (Rosenbaum, 1991).
8
The advantage of using the Mahalanobis distance is that it takes into account the covariance among the variables in
calculation of distances; however, binary elements that are rare can overly influence matching based on
Mahalanobis distances (Rosenbaum and Rubin, 1983). Inclusion of the propensity score in the vector of covariates
can reduce bias in these situations essentially by balancing some deviations between individual covariates with
closer matches on the composite of those covariates as reflected in the propensity score (Rubin and Thomas, 2000).
Given that we know outcomes such as hospitalizations are rare, we include the propensity score in the vector of pretreatment variables.

di , j ≡ ( xi − x j ) C −1 ( xi − x j ) .
Τ

The differences or “distance” matrix, D, is formed with participants as rows and non-participants
as columns and the Mahalanobis distance for each pair in the appropriate cell. In any case where
the difference in propensity score between participant and non-participant is greater than 0.25 of
the standard deviation of the logit of the observed propensity scores, we assign a penalty of 500
units 9 to prevent matching.
In the second step, once the matrix D is constructed, optimal full matching uses an
algorithm based on a minimum-cost network flow to create k to m matches of participants and
non-participants. Essentially, the matching creates sets based on the values in the matrix D, and
allows for a set to contain any number of participants or controls. The optimal match algorithm
considers the group costs associated with a particular matched set. For instance, a match might
be made on the second- or third-closest distance rather than the first because another set would
be worse off if the closest match were made.

Comparison of Health Outcomes
We use health care encounters as markers of asthma exacerbations (undesirable health
care encounters) and of managed or controlled asthma (appropriate health care encounters). First,
we estimate the mean effect of participation on the probabilities of two binary measures of
preventative health care and three binary measures of treatment of asthma exacerbations. In these
five binary measures we account for the matching of participants to non-participants, using a
9

This penalty serves the same function as a caliper (Haviland et al., 2007) where the standard caliper is a quarter of
a standard deviation of the differences in estimated propensity scores (Rosenbaum and Rubin, 1985).

conditional logistic regression to measure the effect of participation in the program within a
matched group. However, individual measures of health care utilization give an incomplete
picture of a child's overall asthma status; ideally, we would compare the evolution of health
status between participants and non-participants. To do this, we create an indicator that captures
the transition between normal and negative asthma states over time, and evaluate the effect of
program participation on this indicator (H=1,2,3,4). We used Proc GLIMMIX to implement
conditional logistic regression for this multinomial outcome. Matched sets were treated as
random intercepts. The reference group was subjects who had stable outcomes before and after
the intervention. This indicator is discussed in more detail below.

3. Study Data
Our data come from the claims database of Alameda Alliance for Health (AAH), a notfor-profit Medicaid umbrella organization that manages and provides health care services for
low-income families in Alameda County. To construct our sample of participants and nonparticipants (controls), we examined all AAH plan members who had a health claim with a
primary diagnosis code for asthma (ICD-9 of 493.x) and were between the ages of 6 and 20 at
the time of service. We divided this set of children into those who had a record of participation in
OKA (n=282) and non-participation (n=8,307). Figure I describes the criteria for inclusion in
either the treatment or comparison group, and how many individuals were excluded at each step.
We randomly assigned each potential control a "start date" based on the actual distribution of
program start dates of participants (see Johnson et al., 2005) 10 to create comparable pre-treatment

10

For instance, if 10 out of 270 children (4%) started OKA in February 2005, we randomly assigned 110 out of
2,742 potential controls (4%) the same start date.

and post-treatment periods. Because asthma symptoms often show seasonal patterns (Gergen et
al., 2002), we consider outcomes at six-months and twelve-months after the intervention.
<<Insert Figure I here>>
Ideally, we would have complete symptom information on participants and nonparticipants. In the absence of these data for non-participants, we created an inventory of health
care utilization measures based on the billing codes for asthma-relevant health service encounters
(summarized in Table A.1 in the appendix) that was as comprehensive as possible. With the
exception of home medical equipment, allergy testing, allergy immunology, and participation in
an asthma program other than OKA, variables were defined as both a binary measure (0=no
encounter, 1=any encounter) and a count of encounters. In addition to health care encounters, we
identified asthma-related prescription drug claims and distinguished between rescue medications
(for use in asthma exacerbation) and controller medications (preventative medication). An
important marker of a significant asthma exacerbation in children is the use of systemic/oral
glucocorticoids (e.g., Prednisone), although these are not limited to asthma treatment; a
prescription for glucocorticoids was included in the measure of steroid use only if it was in
conjunction with a health care encounter with an asthma diagnosis. As with health care
utilization, for each class of medication (rescue, control, systemic steroid), we created both
binary and count variables. In addition, we created indicators of excessive or adequate use based
on recommended doses and prescription volumes. 11 Lastly, we created a medication intensity
scale following Schatz et al (2006). 12 The result is a set of 72 measures of utilization and
prescription use prior to participation in OKA.

11

Information on doses per canister was compiled using a Medline search on each prescription inhaler.
Documentation available from authors by request.
12
To create medication intensity scale, we ran a stepwise logistic regression of number of prescriptions on an
indicator for a visit to the emergency department for asthma. Cut-points in the number of prescriptions were defined

To evaluate an individual's interaction with health providers, we reviewed the primary
care provider (PCP) and specialty codes for all asthma-related claims. To assess continuity of
care, we created counts of the total number of different primary care providers for all asthma
claims within six and twelve months prior to the program start date, as well as an indicator
variable for no PCP assigned. We also created counts of encounters with each of three types of
providers (pulmonologist, allergist, or any respiratory specialist). Lastly, we created an indicator
for whether the child had ever had a claim with an allergy diagnosis. This set of individual
characteristics included a total of nine variables.
The eligibility files for AAH members provided socio-demographic data that included
race/ethnicity, language, age, type of health plan and group, number of others included in the
health plan, and number of adults on the health plan. To account for measurement bias
introduced by gaps in service, we created a marker for those children who had gaps that totaled
more than 65 days in the year prior to or after the program start date. Twenty-eight children in
the treatment group (10%) and 252 children in the potential control group (9%) had gaps in
insurance coverage. We accounted for the potentially missing data that a gap in service might
incur by inclusion of this variable in selection of the participation model using the DSA. There
were eleven socio-demographic measures in total. 13
Finally, to include community level variables, we geocoded our study subjects to the
2000 US Census tract level to describe each child's neighborhood composition. We considered
forty measures that covered age distribution, country of birth, family structure (e.g., percentage
married), employment status, and income characteristics of the neighborhood.

by breaks in the odds ratio for ED visit (see Appendix C for regression results). This approach to defining
medication intensity has been found to be predictive of future utilization.
13
A complete list of the procedure and billing codes used to create each variable is available from the authors upon
request.

In Table I, we describe the basic socioeconomic characteristics of the treatment and nonparticipant groups. Compared to the potential control group, the treatment group had slightly
more Hispanic participants (and more Spanish speakers) and slightly fewer Black and Asian
participants. This difference is perhaps due to recruiting efforts in a local clinic targeting
Spanish-speaking families. The only other notable difference is that a substantially higher
proportion of participants had an allergy diagnosis than non-participants. The small difference in
the age distribution is explained by the program eligibility requirements.
<<Insert Table I here>>
As shown in Table II, the participant and non-participant groups differed in patterns of
health care utilization. Relative to eligible AAH members who had an asthma diagnosis, OKA
participants were more likely to have had an ED visit, outpatient visits, or a prescription for
systemic steroids. A higher proportion of participants fell into the high medication intensity
categories for both rescue and controller medications. Participants were somewhat more likely to
have had an inpatient hospitalization. Interestingly, participants also were more likely to have
had preventative care such as flu or pneumonia vaccines or pulmonary testing. As a group,
participants appear to be heavier users of health care than non-participants.
<<Insert Table II here>>
4. Construction of the Comparison Group
The first step in constructing the comparison between program participants and nonparticipants is to estimate the propensity scores (propensity to participate in the program) of all
individuals based on pre-treatment characteristics. The complete vector of all measures of pretreatment characteristics consisted of 132 elements. We used the DSA to identify the most
informative variables in each domain: health care use, socio-demographics, provider and plan

characteristics and neighborhood composition. We allowed for up to fifteen terms with a
maximum of three interactions and a maximum power of three for each model. First we ran the
DSA separately for each domain of explanatory variables. Next we created a subset of
explanatory variables that were in any of the models that minimized the loss function four or
more times out of all the runs of the data (we used 5 splits of the data for each of the 10 seeds).
Finally we ran the DSA on this subset of variables. The result is a model for program
participation based on a subset of pre-treatment characteristics, x ∈ X , with the maximal
predictive power across the entire set of all such models.
<<Insert Table III here>>
Table III lists the measures for each domain that maximized predictive power as well as
their odds ratios from the logistic regression for participation. Measures of utilization, allergy
diagnosis, and number of different primary care providers have a positive impact on the
probability of participation; 14 the number of adults in the health plan has a negative impact. One
characteristic of note is that the relationship between utilization and probability of participation
is not linear in the variables; this highlights the importance of doing an exhaustive search over
possible models.
While a behavioral model of the participation decision is interesting, the main
importance of the participation regression is derivation of the propensity scores used to match
participants and non-participants. Figure II shows that the propensity scores for the two groups
had little overlap, which makes it more important to use full matching to make full use of the

14

Having an emergency room visit or urgent outpatient visit increased the probability of participation most likely
because it served to highlight the negative outcomes associated with unmanaged asthma. The positive relationship
between having controller medication and an allergy diagnosis and participation could be interpreted in two ways.
Either those children with more severe asthma or comorbidities are more likely to participate, or that individuals
with higher propensity to seek out health services are those who are more likely to participate. The number of
primary care providers is probably capturing many factors that could affect continuity of care.

available data. Optimal full matching (Haviland et al., 2007) 15 yielded 247 matched sets,
matching 266 out of 270 people in the treatment group to 2,739 out of 2,742 in the control
group. 16 The overlap in propensity scores improved significantly, as illustrated in the second
frame of Figure II.
<<Insert Figure II here>>
We also conducted t-tests for each of the pre-treatment variables selected by the DSA
algorithm. Because the relationship between participants and non-participants in each matched
group is not one-to-one, we construct the sum of differences between each pair of individuals (i
and j) within each group and weight this by the inverse of the number of matches within that
group.
x =

Σ kK=1 ( xi − x j ,k )
K

.

The test statistics are reported in Table IV. With the exception of the number of control
medications in the previous six months and number of adult family members with AAH
insurance, the treatment and control groups do not differ significantly. Together, the overlap in
the propensity scores of the two groups and the results of the t-tests suggest that optimal full
matching has substantially reduced the bias in comparing outcomes across the two groups 17.
<<Insert Table IV here>>

15

Using the optmatch package in R.
The matched sets' quartile case : control ratios (.25, .5, .75, 1.0) are 1:13, 1:4, 1:1, 8:1; one matched set contained
eight treated participants and one control. Hence, the total number of matched sets (247) is less than the total of
matched treated participants (266).
17
In addition, we wanted to confirm that our analysis of program outcomes, described in the following section, was
not sensitive to the choice of matching technique. Therefore, we tried several optimal matching combinations
including 1:1, 1:4, 1:k without a penalty, and optimal matching with only propensity score distances and a caliper,
and repeated our regressions of treatment outcomes each time. In each case, the regressions of treatment outcomes
had odds ratios of similar magnitude and direction, regardless of the matching technique. Because optimal full
matching is preferred on statistical grounds, we limit our presentation to only those results, but the results are
qualitatively equivalent for all matching techniques.
16

5. Evaluation Results
First, we use traditional bivariate analysis to measure the impact of the program on
preventative care and treatment for exacerbations. Changes in preventative care are important
intermediary steps to reduce the costly outcomes associated with certain consequences of asthma
exacerbations (e.g., emergency room visits, hospitalization). Table V shows the results of five
conditional logistic regressions for matched participant-control groups. 18
<<Insert Table V here>>
Compared to non-participants, participants were more likely to have engaged in two
measures of risk-reducing behaviors: vaccinations for pulmonary illness (influenza or
pneumonia) and using controller medications. 19 The odds ratios between participants and nonparticipants are 2.95 for vaccinations (1.82 to 4.81, 95% CI) and 1.53 for controller medication
(1.07 to 2.19, 95% CI). These are all promising indicators, and this increase in risk-reducing
behaviors should translate into a reduction in adverse outcomes (asthma exacerbations).
However, out of three indicators of treatment for asthma exacerbations in the six months
following the program - the number of prescriptions for rescue medications, any nebulizer
treatment, and any ED visit - only one is statistically different between the two groups at the 95%
confidence level. The odds of a participant having a prescription filled for a rescue inhaler are
1.49 times greater than for non-participants (1.07 to 2.07). It is unclear how to interpret the
increase in prescriptions for rescue inhalers. Most children with asthma should have a rescue
inhaler on hand in case of an emergency. OKA may have made more families aware of this fact

18

Note that conditional logistic regression for matched case-control groups is equivalent to fixed-effects logit for
panel data; because of the health nature of the study, we will use the term most commonly used in biostatistics.
19
We decided not to consider pulmonary testing because without a detailed chart review there is no way to
accurately categorize this type of encounter as being due to an exacerbation or use as a preventative measure.

and encouraged them to have an adequate number of prescriptions 20 - or OKA participants may
have suffered a higher level of exacerbations, forcing them to refill their prescriptions more
often.
Given the complex nature of asthma, the goal of a program such as OKA should not be
simply to reduce consumption of specific health care services. More broadly, the goal should be
to improve the overall state of a child's asthma. To reflect this priority, we created an indicator
for change (or lack thereof) in asthma state after program participation. A child is considered to
be in a negative asthma state if he or she has had a health care encounter to treat an asthma
exacerbation or has had excessive use of rescue medication; otherwise he or she is in a stable
asthma state. This definition is based on the Global Initiative on Asthma (GINA) and is similar
to indices used in other studies of asthma exacerbations (see Price and Briggs, 2002 and Stempel
et al., 2005). Since there are two possible states before and after participation, Hi has four
possible values, as illustrated in Figure III. 21 Our approach is conservative, because a person is
coded as being in a negative state if he or she has any encounter that indicates an asthma
exacerbation. We use a strict definition for asthma control because we do not want to
overestimate a treatment effect.
<<Insert Figure III here>>
We then estimated a conditional multinomial logit using Proc Glimmix where the outcome is the
individual's score of the index. Table VI reports the probabilities of the four possible
20

For example, a child may need to have an inhaler at home and school. If prior to OKA the child did not have an
inhaler at one of those places, or had an expired inhaler, then adding an inhaler after OKA is actually a risk-reducing
behavior.
21
The four possible values are strongly and logically associated with changes in direct health care costs discussed in
the previous section. Recall that the mean decrease in costs for all OKA participants was $133. Participants who
worsened had a mean increase of $166, while those who improved had a mean decrease of $377. Those who
remained stable over both periods had a mean increase of $2, and those who remained in the negative state had a
decrease of $65. Because these numbers are not relative to the control group, they do not reflect the impact of the
program itself. However, they show the benefit to be gained by moving children from the negative to the stable
state.

combinations of pre- and post-treatment states for the participants and non-participants. As
previously discussed, asthma is a chronic disease with episodic symptoms. With perfect asthma
control, an individual would stay in the stable state over time. In reality, asthma severity and risk
reducing behaviors vary over time and individuals will move between stable and negative states.
The statistics in Table VI illustrate how in the absence of an intervention a comparable group of
children with asthma are distributed between stable and negative states over the two time periods
relative to the intervention. The greatest share of non-participants (49%) were in a stable asthma
state before intervention and stayed in that state after the intervention, and 20% of nonparticipants worsened over the two periods. A smaller proportion of children who participated in
the intervention started and remained in the stable states (30%), and 19% of participants
worsened over the periods. There was no statistically significant difference in the conditional
probability of worsening (moving into a negative state given a stable state initially) between the
participants (0.39, 95% CI 0.28 to 0.52) and non-participants (0.29, 95% CI 0.27, 0.32).
Likewise there is no statistically significant difference between participants and non-participants
in the conditional probability of remaining stable given a stable initial state. A higher proportion
of participants started in a negative state than non-participants, but again the difference is not
statistically significant. However, there is a statistically significant difference in the conditional
probability of improving given that the initial state was negative. The conditional probability of
improving was 0.39 (0.3874, 0.3922) for participants and 0.49 (0.4867, 0.5021) for nonparticipants.
<<Insert Table VI here>>

6. Discussion
Our evaluation of Oakland Kicks Asthma demonstrates the challenges of validating the
case management approach. We determined that program participants are more likely than nonparticipants to use two types of recommended preventative health care - control medications and
vaccines for respiratory infections - which could be due to greater awareness that asthma can be
managed. However, we found no reduction in treatments for asthma exacerbations, and an
increase in filling prescriptions for rescue medications. This increase may have been due to
families updating expired prescriptions or obtaining new prescriptions to have rescue medication
available at school, as suggested by discussions with OKA program managers, which would be a
positive outcome, but this cannot be verified using the claims data available. A reduction in
nebulizer treatments and ED visits, the other markers of asthma exacerbations, would be difficult
to find in any case. First, these are uncommon events to begin with. Second, any long-term
benefits of improved preventative care would only appear over a longer time frame. 22 For these
reasons, even a successful program could lead to an increase in utilization in the short term,
before any long-term decrease in utilization becomes visible.
Alternatively a program could be effective for some segments of the target population but
ineffective for others, making its impact statistically insignificant for the group of participants as
a whole. Schuck and Zeckhauser (2006) characterize the inefficiencies (both economic and
political) generated by not targeting social programs to those for whom the programs will do the
most good. 23 However, additional research can help us better understand these differences and
thereby improve programs and outcomes.

22

This limitation is evident in previous studies as well (see Evans et al., 1999; Harish et al., 2001; Krieger et al.,
2005, and Morgan et al., 2004).
23
Schuck and Zeckhauser differentiate between those individuals who derive little benefit either relative to the
resources consumed or relative to others in the program (bad best) from those individuals who actually impose

It is also plausible that the program did improve some outcomes, but that we were not
able to measure those changes using our administrative data. The issue of measurement is
complicated because the strength of the research design is the ability to compare the participants
to non-participants who are similar in all other relevant dimensions. Typically these data are
taken from administrative or insurance records. Measuring other changes (e.g., quality of life)
would require surveying both participants and non-participants.
Finally, the program may have faced structural challenges beyond its potential reach that
prevented it from achieving its desired outcomes. One possible barrier is failure of physicians to
follow best practice. Despite efforts to publicize and encourage physicians to implement existing
asthma management guidelines, there is significant empirical evidence that physician compliance
is low. A second potential barrier is household dysfunction that prevents effective management
(Perry 2008).

7. Conclusion
The National Cooperative Inner City Asthma Study has given rise to a major wave of
public investment in asthma intervention programs that use case management to affect household
behaviors. We used a rigorous methodology to evaluate the Oakland Kicks Asthma program
based on optimal matching that incorporated propensity score matching to construct a control
group to compare to the group of program participants. In short, our evaluation finds that OKA
has no significant effect on participants that distinguishes them from the control group, whether
we look at utilization or transitions between negative and stable asthma states. This analysis
raised a number of questions that it could not answer, because there are several competing

externalities on other participants (bad apples). We are primarily interested in avoiding bad bets because most of the
asthma programs are focused on small groups or individuals.

explanations for not finding statistically significant changes in outcomes. Asthma programs
funded by the CDC share a common approach to data collection and program evaluation – i.e.,
one that focuses on administrative measures rather than actual outcomes – therefore these
uncertainties cannot be addressed even with the data aggregation over all of the various programs
that are part of CAACP.
To determine whether this type is asthma management intervention is effective, public
health researchers need to be able to rule out several competing explanations for not finding
statistically significant changes in outcomes: (1) the post-intervention time period may be too
short to see changes; (2) utilization data miss relevant changes; (3) even if the program has no
significant impact on average, it may have a positive impact on a segment of participants; (4)
structural barriers beyond the scope of the program may limit its impact; or (5) the program is
not effective. Which of these possible explanations are appropriate requires a broad range of data
about both participants and non-participants over an adequately long time-frame. In addition to
improving the accuracy of the evaluation, these data would enable us to construct a richer model
of the causal relationships between program attributes, participant behaviors, and outcomes.
Then asthma intervention programs could be shaped to increase overall effectiveness and to
target those participants who are most likely to benefit.
We recommend three changes to how these national programs are implemented. First,
resources must be invested in collecting long-run, detailed data on both participants and nonparticipants thus improving the measurement of changes on the individual or household-level
otherwise not captured in administrative data. Second, more research is needed to identify
individual or household characteristics that increase the probability of a positive outcome due to
the program. Third, the program can itself be targeted at those who are likely to derive a benefit

from participation. For example, one could design a two-stage program that provides a low-cost,
group education program for any eligible household and then a second, more intensive and more
costly, individualized intervention for the more committed families. This program design does
reduce the total number of participants in the personalized program, but can increase the
proportion that will see benefits and therefore increase the program's return on investment. Such
a shift in the collection and usage of program data will both increase the public health benefits of
the CDC's asthma programs and make it possible to shift resources toward those intervention
models that are proven to succeed.
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Figure II: Box plot of propensity score before and after matching
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Figure III: Transitions between asthma states
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Table I. Demographics of study participants (n=3,012)
Treatment group
n (%)

Control group
n (%)

Black

139 (51)

1,515 (55)

Hispanic

96 (36)

736 (27)

Asian

35 (13)

491 (18)

155 (57)

1,778 (65)

Asian group

25 (9)

371 (14)

Spanish

88 (33)

593 (22)

2 (1)

0 (0)

Male

147 (54)

1,446 (53)

Female

123 (46)

1,296 (47)

2-11

103 (38)

1,234 (45)

12-16

148 (55)

1,024 (37)

17-22

19 (7)

484 (18)

No

103 (38)

1,664 (61)

Yes

167 (62)

1,078 (39)

Race/ethnicity

Language
English

Missing/unknown
Gender

Age group at study start*

Allergy diagnosis

N
270
2,742
*The treatment group age range is 6-19, while the potential control group range is 2-22. Participants in both groups
were born between 1985 and 2000, but the control group had a greater age at the study start due to the random
assignment of start dates. Age was not selected by the DSA for being associated with OKA participation.
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Table II: Health care use by treatment and control groups 1 year prior to enrollment
HEDIS adapted variables
Asthma-related health care

Treatment group
n (%)

Control group
n (%)

0

210 (78)

2,568 (94)

≥1

60 (22)

174 (6)

0

255 (94)

2,709 (99)

≥1

15 (6)

33 (1)

0

108 (40)

1,831 (67)

≥1

162 (60)

911 (33)

0

226 (84)

2,509 (92)

1 or 2

43 (16)

233 (8)

0

218 (81)

2,545 (93)

≥1

52 (19)

197 (7)

0

196 (73)

2,464 (90)

≥1

74 (27)

278 (10)

0

61 (23)

1,468 (54)

1-8

175 (65)

1,208 (44)

>8

34 (13)

66 (2)

0

104 (39)

1,997 (73)

1-2

65 (24)

403 (15)

>2

101 (37)

342 (12)

270

2,742

Emergency department or
urgent care visits

Inpatient hospitalization

Outpatient or MD office visits

Flu or pneumonia vaccine

Prednisone prescriptions

Pulmonary tests

Rescue prescriptions

Control prescriptions

N
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Table III. Propensity score model (with OKA participation as the outcome)
Pre-treatment characteristics

Odds Ratio, Standard Error, [95% CI]

Utilization and prescriptions
# of control medications in the previous 6 months*

1.14, 0.04, [1.06, 1.22]

Any control medication in the previous year*

1.55, 0.27, [1.10, 2.19]

# of ED or urgent care visits for asthma in the previous
6 months (squared)

4.51, 1.90, [1.97, 10.30]

# of ED or urgent care visits for asthma in the previous
6 months (cubed)

0.56, 0.12, [0.36, 0.86]

# of outpatient visits for asthma in the previous year*
(squared)

1.02, 0.01, [1.01, 1.03]

Interaction with health care providers
# different primary care physicians listed for a child in
previous 6 months

5.89, 2.87, [2.27, 15.31]

# different primary care physicians listed for a child in
6 months (squared)

0.39, 0.17, [0.17, 0.90]

Individual ever had an allergy diagnosis

1.75, 0.25, [1.32, 2.31]

Socio-economic and demographic
# adult family members with AAH health insurance

0.76, 0.07, [0.64, 0.91]

% households in a study participant’s census tract with
income between 25-50k** (cubed)

1.00, 0.00, [1.00, 1.00]

*HEDIS defined variable
**Rounded to the nearest hundredth
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Table IV. T-test results of covariate balance based on weighted distribution among
matched sets
Variables

Mean difference

t-statistic

# outpatient visits for asthma in the previous
year* (squared)

-0.45

-1.01

# ER or urgent care visits for asthma in the
previous 6 months (squared)

0.00

-0.02

# control medications in the previous 6 months*

-0.13

-2.18

# different primary care physicians listed for a
child in previous 6 months

0.02

1.17

# adult family members with AAH health
insurance

-0.09

-1.83

Allergy diagnosis (proportion)

0.02

0.77

# different primary care physicians listed for a
child in 6 months (squared)

0.02

0.89

% households in a study participant’s census
tract with income between 25-50k (cubed)

331.22

1.08

Any control medication in the previous year*

-0.04

-2.51

# ER or urgent care visits for asthma in the
previous 6 months (cubed)

0.00

0.03

*HEDIS defined variable
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Table V. Bivariate odds ratios for outcomes from conditional logistic regression after OKA case management treatment
Outcome

Observations (n),
matched sets

OR

Likelihood
Ratio

90% CI

95% CI

Standard
Error

# of control medication 6 months
post

2359, 172 sets

1.53

-761.28

[1.13, 2.07]

[1.07, 2.19]

0.28

Any flu or pneumonia vaccine 1
year post

1507, 110 sets

2.95

-316.73

[1.97, 4.45]

[1.82, 4.81]

0.73

# of rescue medication 6 months
post

2511, 183 sets

1.49

-1154.9

[1.13, 1.96]

[1.07, 2.07]

0.25

Any nebulizer administration 6
months post

1462, 66 sets

1.93

-230.84

[1.09, 3.42]

[0.98, 3.81]

0.67

Any ED or urgent care center visit
for asthma 6 months post

1501, 70 sets

1.73

-259.98

[1.00, 3.00]

[0.90, 3.33]

0.58

Preventative Care

Treatment of exacerbation
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Table VI: Probabilities of asthma states
Prior to intervention  Post intervention

Participants (95% CI)

Non-participants (95% CI)

Stable state Stable state

0.30 (0.18, 0.45)

0.49 (0.44, 0.54)

Stable state  Negative state

0.19 (0.17, 0.20)

0.20 (0.20, 0.20)*

Negative state  Negative state

0.31 (0.23, 0.38)

0.16 (0.13, 0.19)

Negative state  Stable state

0.20 (0.15, 0.24)

0.15 (0.13, 0.18)

* Due to rounding.

These probabilities are derived from the conditional multinomial logit estimated using Proc
Glimmix in SAS.
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Appendix
Table A1: Utilization measures
Utilization measures

ICD-9 procedure codes

Inpatient admissions
(HEDIS defined*)
Emergency Department
(HEDIS defined)
Outpatient visits
(HEDIS defined)
Inpatient admission
Treatment codes

99221-99223, 99231-99233, 99238-99239, 99251-99255, 9926199263, 99291-99292, 99356-99357
99281-99285, 99288

Inpatient treatment
Emergency Department or
Urgent Care visit
Emergency Department or
Urgent Care treatment
Outpatient or physician’s
office visit
Outpatient or physician’s
office treatment
Flu or pneumonia vaccine
Nebulizer use
Pulmonary testing

Home medical equipment
Allergy testing
Allergy immunotherapy
Other asthma education (not
OKA)
High severity visits to
outpatient facility or
doctor’s office
Ambulance service

Binary
Only

99201-99205, 99211-99215, 99217-99220, 99241-99245, 9927199275
HEDIS codes plus 99235- 99236
90772, 90774, 90782, 94002-94004, 94640, 94642, 94644-94645,
94660, 94662, 94665, 31500, 83735, 4025F, J1100, J1030, J7506,
J7510, J7611,J7613-J7614, J7616, J7618- J7621, J7625- J7626,
J7644,
X5528, X5530, X5554 , X6004, X6008, X6014, X6036, X6038,
X6328, X6580, J7510, E0570, E0570
Any treatment code combined with inpatient hospital as place of
service
HEDIS codes plus 90760, 96150-96151, 99062, 99064-99065,
99236, , 99382-99384, 99394-99393, 450, Z7502, Z7610
Any treatment code combined with emergency room or urgent
care center as place of service
94664, 96150-96151, 99234, 99348, 99371-99374, 99382-99385,
99392-99395
Any treatment code combined with physician office or outpatient
center as place of service
90655-90660, 90669, 90724, 90732
94640
92551-92552, 94010-94016, 94060, 94070, 94150, 94160, 94200,
94375, 94620-94621, 94680, 94681, 94690, 94750, 94760-94762,
94799, 95012, 95070, 95071, 82803, 82805, 31622, 31646, 3023F,
3025F, 3027F, 3028F, 3035F, 3037F, 71010-71555, A4614,
9944A, E1390, E0570, E0431, A9900, A7003, E0550, A7005,
A7004
94200, 94240, 95004, 95010, 95015, 95024, 95027, 95044, 95070,
95075, 86001, 86003, 86005, 0168T
95115, 95117, 95144-95149, 95165, 95170, 95199
96150, 96151, 96155

X
X
X
X

99354, 99355, 99058, 99060, 99220, 99235, 99236

X0036, A0800, 99289, X0030, A0434

* Source: Healthcare Effectiveness Data and Information Set (HEDIS).
Note: We felt that the HEDIS criteria were overly restrictive for our purposes, and we relaxed the HEDIS criteria to
generate a second set of amended-HEDIS measures for ED visit, inpatient admission, and outpatient/doctor’s office

visit. Our adapted HEDIS definitions generally were more inclusive and contained more procedure and point of
service codes than HEDIS. With the exception of home medical equipment, allergy testing, allergy immunology,
and participation in asthma program other than OKA, variables were defined as both a binary measure of any
encounter (0= no encounter, 1=any encounter) and a count of encounters. All variables are measured at 6 month and
one year intervals.

Table A2: Medication intensity scale

Rescue
prescriptions 1
year prior to
enrollment for
eligible cases and
controls
>0
>1
>2
>3
>4
>5
>6
>7
>8
>9
>10
>11
>12
>13
>14
>15

OR for an ED
SE
visit 1 year after
treatment

95% CI

1.18
1.25
1.17
1.17
1.19
1.33
1.71
1.84
2.64
2.70
2.97
2.33
2.71
2.37
2.88
4.50

[0.85, 1.64]
[0.88, 1.76]
[0.79, 1.75]
[0.74, 1.85]
[0.70, 2.01]
[0.76, 2.33]
[0.96, 3.06]
[0.96, 3.53]
[1.35, 5.13]
[1.29, 5.62]
[1.36, 6.50]
[0.89, 6.12]
[1.02, 7.19]
[0.69, 8.18]
[0.82, 10.14]
[1.20, 16.78]

0.20
0.22
0.24
0.28
0.32
0.38
0.51
0.61
0.90
1.01
1.18
1.15
1.35
1.50
1.85
3.02

This is an application of Schatz et al.’s work (2006) to estimate categories of medication use where there is a change
in the odds of an ED visit. We created variables in Table II for rescue medication use (0, 1-8, and >8) where there
were larger OR differences. We wanted to differentiate between children who were properly using their rescue
medication and those who were not. We also included these categories in the DSA to model program participation.
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